Statin Therapy for Type 1 Diabetes Mellitus Patients

Risk Assessment and Statin Indications for T1DM

The European Society of Cardiology recommends that statins may be considered in asymptomatic patients with Type 1 Diabetes Mellitus (T1DM) aged >30 years, but are not routinely recommended for all T1DM patients 1
For T1DM patients aged 20-39 years, the American Diabetes Association suggests that statin therapy should be considered only if there are additional atherosclerotic cardiovascular disease (ASCVD) risk factors 2
For T1DM patients aged 40-75 years without established ASCVD, the American Diabetes Association recommends moderate-intensity statin therapy (such as atorvastatin 10-20 mg) in addition to lifestyle therapy 3, 2
For T1DM patients with established ASCVD at any age, the American Diabetes Association recommends high-intensity statin therapy (atorvastatin 40-80 mg) 4, 5
The European Society of Cardiology states that statins are contraindicated in women of childbearing potential due to potential teratogenic effects 1, 6

The Heart Protection Study, which included approximately 600 patients with T1DM, showed a proportionately similar, although not statistically significant, reduction in cardiovascular risk compared to patients with T2DM 2

For moderate-intensity statin therapy, the American Diabetes Association recommends atorvastatin 10-20 mg daily 3, 2
For high-intensity statin therapy (in those with established ASCVD), the American Diabetes Association recommends atorvastatin 40-80 mg daily 3, 5

If LDL-C targets are not achieved with maximum tolerated statin dose, the European Society of Cardiology suggests considering adding ezetimibe 6, 4
The American Diabetes Association recommends obtaining lipid profile at initiation of statin therapy, 4-12 weeks after initiation or dose change, and annually thereafter 3

The American Diabetes Association recommends that the risk-benefit profile should be routinely evaluated in patients aged >75 years, with downward titration of dose performed as needed 5